GTC Biotherapeutics Collaborates With LFB Biotechnologies
GTC Biotherapeutics (Framingham, MA, http://www.gtc-bio.com) and LFB Biotechnologies (France) have signed an agreement to collaborate in the development of selected recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform.
GTC Biotherapeutics (Framingham, MA, http://www.gtc-bio.com) and LFB Biotechnologies (France) have signed an agreement to collaborate in the development of selected recombinant plasma proteins and monoclonal antibodies using GTC’s transgenic production platform. A joint steering committee will agree on product development and commercialization plans.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
